Zoetis Inc.
No SEC Form 4 filings for $ZTS in the last 30 days.
Zoetis Inc. appointed James “Jay” Saccaro as executive vice president, CFO and COO effective Aug. 17, combining global finance oversight with responsibility for manufacturing and supply chain operations. Current CFO Wetteny Joseph steps down Aug. 17 and stays as special advisor through early 2027. Zoetis reported $2.5B in Q2 revenue.
Zoetis reported U.S. revenue down 7% and U.S. Companion Animal down 11% in Q2 2026, citing fewer vet visits and heavier discounting by competitors. Full-year organic operational revenue guidance revised to a 3% to 1% decline. Diagnostics grew 12%. Zoetis plans continued gross-to-net promotions, FX headwinds of $60m to $65m, and a buyback over $550m.
Zoetis Inc. (ZTS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 d166736dex102.htm EX-10.2 EX-10.2 Exhibit 10.2 10 Sylvan Way Parsippany, NJ 07054 July 31, 2026 Dear Wetteny: On behalf of Zoetis Inc. (the “ Company ”) and its Board of Directors, I want to thank you for your years of service and contributions to the Company and for ag
Over the past 7 days, alphai's AI scored 8 news stories mentioning ZTS (Zoetis Inc.). Coverage has skewed bearish: 0 bullish, 3 neutral, and 5 bearish.
Recent ZTS coverage spans earnings, financial news and sector analysis.
The role consolidation signals tighter integration of capital allocation with manufacturing and supply chain execution, potentially affecting near-term operational priorities and cost discipline.
Guidance reset plus continued gross-to-net promotions suggests near-term volume defense over margin expansion, keeping downside risk elevated until stabilization signals appear.
The filing is a structured executive transition with severance and incentive details, which can affect near-term governance and financial reporting continuity expectations.
Revenue miss and below-consensus full-year guidance are likely to pressure near-term expectations despite EPS holding near consensus.
Guidance reset signals weaker demand or margin pressure, likely increasing near-term earnings risk and valuation sensitivity.
alphai scores every news story that mentions ZTS with an AI model for sentiment and relevance, and aggregates insider trades from Zoetis Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Zoetis Inc. appointed James “Jay” Saccaro as executive vice president, CFO and COO effective Aug. 17, combining global finance oversight with responsibility for manufacturing and supply chain operations. Current CFO Wetteny Joseph steps down Aug. 17 and stays as special advisor through early 2027. Zoetis reported $2.5B in Q2 revenue.
2 min readZoetis reported U.S. revenue down 7% and U.S. Companion Animal down 11% in Q2 2026, citing fewer vet visits and heavier discounting by competitors. Full-year organic operational revenue guidance revised to a 3% to 1% decline. Diagnostics grew 12%. Zoetis plans continued gross-to-net promotions, FX headwinds of $60m to $65m, and a buyback over $550m.
7 min readZoetis Inc. (ZTS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 d166736dex102.htm EX-10.2 EX-10.2 Exhibit 10.2 10 Sylvan Way Parsippany, NJ 07054 July 31, 2026 Dear Wetteny: On behalf of Zoetis Inc. (the “ Company ”) and its Board of Directors, I want to thank you for your years of service and contributions to the Company and for ag
3 min readZoetis (NYSE:ZTS) reported Q2 CY2026 sales of $2.47 billion, flat year on year, and below market expectations. The company’s full-year revenue guidance midpoint of $9.22 billion was 5.4% below analysts’ estimates. Non-GAAP adjusted EPS was $1.87, up from $1.76, about in line with consensus.
6 min readZoetis (ZTS) reported Q2 results and cut its FY2026 guidance due to the current operating environment. It now expects EPS of $5.55 to $5.65 and adjusted EPS of $6.15 to $6.25 on revenue of $9.12B to $9.32B, with organic revenue down 3% to 1%. Prior outlook was higher. ZTS traded at about $76.00 premarket.
2 min readZoetis Inc. (ZTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit99q22026.htm EX-99.1 Document EXHIBIT 99.1 Zoetis Announces Second Quarter 2026 Results • Revenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis • Adjusted Net In
7 min readZoetis shares fell 47.6% over 52 weeks and 38.6% YTD, but are up 8.16% from a June 30 52-week low of $71.47. In Q1 2026, revenue rose 3% to $2.26B and non-GAAP EPS rose 9% to $1.53, with U.S. revenue down 8% YOY. Guidance: revenue $9.68B-$9.96B, EPS $6.85-$7.00. Analysts’ consensus target is $107.19.
6 min readDiamond Hill Capital’s Q2 2026 Large Cap Strategy investor letter said Zoetis (ZTS) detracted after it reported flat organic revenue growth and lowered full-year guidance, citing softer US companion-animal demand, fewer veterinary visits, and more competition. The article notes ZTS closed at $77.29 on July 31, 2026, with a $32.4B market cap.
2 min readBank of America said animal health stocks face continued 2Q26 pressure from fewer veterinary visits and higher drug competition. It kept Elanco Animal Health (Elanco) as its top pick with a buy rating, while maintaining neutral ratings on Zoetis and Idexx Laboratories. VetSource data showed Q2 visits down 1.9% YoY and July down 4% YoY. BofA expects FY2026 visits to fall about 2% and sees Elanco pricing rising below Zoetis.
4 min readUBS said Elanco Animal Health is its strongest animal health pick for Q2, citing US pet healthcare momentum through May and early market share gains for Credelio Quattro. UBS expects Q2 revenue above expectations and a potential full-year guidance raise, kept a buy rating and set a $31 price target versus $25.33. UBS was neutral on IDEXX and Zoetis.
2 min read
